Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) [Phase 3]

View source ↗

Summary

Phase 3 LUCERNE trial evaluated the efficacy and safety of Faricimab in neovascular age-related macular degeneration; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• VABYSMO (faricimab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Wet Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2022-05-04